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Topical application  of picryl chloride  (PCL), 1 the chemically reactive form of the 
trinitrophenyl  (TNP)  hapten,  regularly  induces  a  contact  hypersensitivity  reaction 
(CS)  that  is of the  long-lived type  (>3  wk)  (1).  However, when  TNP  is coupled to 
cells in vitro and these cells are used for immunization, three different immunological 
outcomes may ensue depending on the route of administration  and the type of cell to 
which TNP  is coupled.  One outcome is  the  development  of specific immunological 
unresponsiveness  (tolerance).  This  results  when  TNP-coupled  lymphocytes or mac- 
rophages  (peritoneal-exudate  cells,  PEC)  are  injected  intravenously and  is probably 
a  result of the induction of specific suppressor T  cells (1-3). A  second outcome is the 
development of an evanescent  form of CS that results when TNP-PEC are adminis- 
tered under conditions that avoid rapid activation of the suppressor circuit. This can 
be  done  by  pretreating  recipient  mice  with  a  low  dose  of cyclophosphamide  or 
injecting the TNP-labeled  cells subcutaneously so that  the initial  contact of antigen 
with the immune system takes place in the draining lymph nodes rather than  in the 
spleen  (1-3). 
A  third  outcome  is  the  development  of a  long-lived  form of CS,  similar  to  that 
achieved  by topical  application  of PCL.  This  form of immunity  also  occurs when 
TNP-coupled epidermal Langerhans cells are used for immunization, even when these 
cells are  injected  intravenously and no cyclophosphamide is used  (1).  In fact, TNP- 
coupled Langerhans cells induce CS when coadministered with an immunosuppressive 
inoculum of TNP-PEC. This implies  that antigen presentation  on Langerhans cells, 
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both  in their normal anatomic position  (i.e.,  the skin)  or when placed in a  different 
anatomic site (i.e.,  the spleen), activate effector cells that are relatively resistant to the 
T  cell-mediated suppression  induced by the TNP-PEC. 
To better understand these findings we asked four relevant experimental  questions: 
(a)  Are there  other normally occurring antigen-presenting  cells with  characteristics 
similar to Langerhans cells? (b)  If so, can more stringent criteria be used to establish 
that the sensitized cells induced by such antigen presentation  are indeed resistant  to 
suppression?  (c) can active antigen-presenting cells (APC) be induced into an inflam- 
matory exudate by environmental  agents?  (d)  if so, could the induction of these cells 
explain  the  mode of action  of certain  adjuvants?  To approach  question  a  we used 
TNP-coupled  splenic  dendritic  cells  (DC)  as  a  source  of immunogen  because  they 
represent  an "endogenous" component of lymphoid tissue  that  always express large 
amounts of Ia and H-2D in the resting state (4), are extremely active as accessory cells 
(5), and present  their own alloantigens in an especially immunogenic way (4).  These 
are  attributes  that  one  would  expect  to  find  in  specialized  APC.  Question  b  was 
approached  in  two  ways:  first  by  coimmunizing  mice  with  a  tolerogenic  dose  of 
trinitrobenzene sulfonic acid (TNBS), known to induce TNP-specific suppressor cells 
(6),  and second by adoptive transfer of cells immunized  by intravenous  injection  of 
hapten-labeled  APC into naive recipients whose inducible suppressor cell population 
remains  intact.  Questions  c  and  d  were  approached  by  comparing  the  immune 
response  produced  by  TNP-coupled  PEC  that  had  been  induced  by  the  potent 
adjuvant complete Freund's adjuvant  (CFA), with the response induced by similarly 
labeled  PEC that had been induced with a  less potent adjuvant  or an adjuvant  that 
leads to an "evanescent" or easily suppressible immune responses such as incomplete 
Freund's adjuvant  (IFA). 
We  found  that  the  intravenous  injection  of TNP-DC  and  TNP-CFA-PEC,  in 
contradistinction  to  other  TNP-coupled  cells,  produced  an  immune  response  that 
could not  be suppressed  by coadministration  of an  intravenous  injection  of TNBS. 
Thus, naturally occurring specialized APC, as well as those induced by mycobacteria, 
activate effector cells that are relatively resistant  to suppression. 
Materials  and Methods 
Animals.  Inbred CBA/J mice of both sexes were obtained  from The Jackson Laboratory 
(Bar Harbor, ME) at 6-8 wk of age and were rested 1 wk in an air-filtered enclosure before use. 
In any one experiment, mice were matched for both age and sex. 
Reagents.  PCL (Eastman Organic Chemicals, Rochester, NY) was recrystallized three times 
from methanol  before  use,  and  was  protected  from  light  during  storage.  TNBS  (Eastman 
Organic Chemicals) was used without further purification. A  10 mM TNBS stock solution was 
prepared so as to be isosomotic for cells (and, therefore, not to cause significant cell lysis) in the 
following way: 290 mg TNBS was dissolved in 70 ml phosphate-buffered saline (PBS). The pH 
of this solution was adjusted to 7.2 by the addition of 5 ml 0.5 M  K2HPO4. To bring the final 
vol to 100 ml,  15 ml of double-distilled water was added, followed by 10 ml of PBS. The final 
osmolality was 310 mOsmol/liter. This solution was then filtered through a 0.45-p.m Millipore 
filter (Millipore Corp., Bedford, MA), and stored in 5-ml aliquots at -70°C. Freshly prepared 
TNBS was generally toxic for cells  (>50% cells killed).  After 2 wk in the freezer,  toxicity was 
substantially reduced to 10-20%. 
Isolation of Splenic DC and Splenic Macrophages (Mdp).  DC or M4~ were enriched from spleen 
adherent  cells  as  described  previously  (7). Spleen  adherent  cells  were  cultured  overnight, 
rosetted  with  antibody-coated erythrocytes, and  separated  into Fc-  (DC enriched)  and  Fc  + 
(M4~ enriched)  components. Bound erythrocytes were removed by lysis in 0.83% ammonium 1346  SPECIALIZED ANTIGEN-PRESENTING CELLS 
chloride. The cells in the DC-enriched fraction are >90%  DC as assessed by cytologic criteria 
and absence of several Mq~ and lymphocyte surface markers  (4,  7, 8). 
Induction of Peritoneal Exudates.  PEC  were  harvested  5  d  after  intraperitoneal  injection  of 
various quantities of stimulators:  (a) 0.5 ml H37LRa CFA or IFA (Difco Laboratories, Detroit, 
MI). Only the oil phase was injected, without emulsification with saline. (b) Bordetella pertussis 
vaccine  (2  ×  108  dead  organisms)  (Department  of Public  Health,  Boston,  MA).  (c)  3  ml 
thioglycollate medium  (Difco Laboratories).  Cells were  removed  from  the  peritoneum  after 
lavage with 5 ml Hanks' balanced salt solution  (HBSS) containing 5% fetal calf serum  (Gibco 
Laboratories, Grand Island Biological Co., Grand IHand, NY). 
Hapten Labeling of Cells.  Cells were suspended in PBS (pH 7.3)  at a concentration of 108/ml 
before the addition of an equal volume of 10 mM TNBS. Trinitrophenylation was carried out 
for 10 min at 37°C. Further hapten coupling was inhibited by the addition of HBSS containing 
10%  fetal calf serum.  Cells were washed  three times with HBSS and  viability, as assessed  by 
trypan blue exclusion, was usually 80-90%. Total cell recoveries after hapten  coupling ranged 
between 70 and 90%. 
,Sensitization of PCL.  Mice were sensitized  by  topical  application  of 0.1  ml  of a  5%  PCL 
solution in absolute ethanol to the shaved abdomen and four footpads. 
Induction of Unresponsiveness to PCL with TNBS.  Specific unresponsiveness to PCL sensitization 
was induced by intravenous injection of 4 mg TNBS in 0.2 ml PBS. When hapten-coupled cells 
were administered at the same time, they were injected in the tail vein. Several minutes later, 
TNBS was injected into the retroorbital plexus. 
Induction of CS Immunity or Unresponsiveness by Cell-bound Hapten.  CBA/J mice were injected 
intravenously with varying numbers of hapten-conjugated cells in 0.2 ml HBSS. 7,  14, and 21 
d  later, control ear thickness was measured with an engineer's micrometer (L. S. Starrett Co., 
Athol, MA)  before application of 10-/tl  doses of a  1% PCL solution  (dissolved in olive oil) to 
each side of both ears. The increment in ear thickness was then measured at various times after 
challenge. CS responses induced by hapten-conjugated cells, like CS induced by painting with 
PCL, were absent at 4 h, were evident by  18 h, persisted at 24 h, and by 48 h  were decreased 
but still significant. 
Only  CS  responses  24  h  after  ear challenge of immunized  groups  are  presented.  In  each 
experiment a  separate group of nonimmune controls was challenged simultaneously with  1% 
PCL  in  olive oil and  their  resulting  24-h  ear swelling responses,  which  varied  from  2-10% 
increases,  were  subtracted  from  that  of each  immunized  group  to  obtain  the  net  percent 
increase, which was rounded off to the nearest  integer. The statistical significance of the data 
was calculated using the two-tailed Student's t test with n -  2 degrees of freedom, where n = 
the number of mice per experimental group. 
Adoptive Transfer of CS.  Spleens and  lymph nodes were removed from mice that  were skin 
sensitized with PCL 7 d  previously. Only spleens from mice immunized for the same length of 
time by intravenous  injection of hapten-coupled  cells were removed. Control ear thickness of 
the untreated CBA/J recipients was measured before mice were injected intravenously with 5 
×  107 immune cells. Within  l h of cell transfer, ears were painted with 1% PCL. The increment 
in ear thickness was measured 24 h  after challenge. 
Estimation of the  TNP Content of Coupled cells by 1z~I-MOPC 315 binding.  125I-labeled  MOPC 
315  prepared  as  described  by  Zeldis et  al.  (9)  was  the  kind  gift  of Dr.  Robert  Rosenstein 
(Department  of Pathology,  Yale University School of Medicine,  New  Haven,  CT).  5  ×  106 
hapten-coupled cells were incubated with an excess of 125I-MOPC 315  (sp act -  1.8 ×  10  ~ Ci/ 
mol)  for  30  min  at  4°C.  Cells  were  washed  extensively and  transferred  to  clean  tubes  for 
counting.  The number  of counts  bound  permits comparison of the relative TNP  density  on 
different cell types, provided they are about the same size and are labeled homogeneously. 
Results 
Studies  on CS Induced by Naturally Occurring Cells  Coupled with  TNP (Table I).  Spleen 
adherent  cells werre  cultured  overnight,  dislodged  from  the  surface,  and  separated 
into DC-rich  (Fc-)  and  Mth-rich  (Fc  +)  fractions  by rosetting with opsonized  erythro- 
cytes.  TNP-conjugated  DC  administered  intravenously  induced  a  CS  reaction  that BRITZ,  ASKENASE,  PTAK,  STEINMAN,  AND  GERSHON  1347 
Group 
TABLE  I 
Induction of Long-lived CS by Intravenous Administration of 
TNP-coupled Splenic DC* 
TNP-coupled spleen ceils 
injected intravenously 
24-h net percent increase 
in ear swelling +  SD:~ 
Type  Number  Day 7  Day 21 
A  DC  (3×  10  n)  11+3  10+2 
B  DC  (7 ×  10')  4 :t: 1  12:1:0 
C  Me  (3 × 10  5)  0  0 
D  M4~  (7 x  10  4)  0.5 :I: I  ND§ 
* Results are from two separate experiments: one in which 4-6 mice per gr~ 
were tested on day 7, and the other in which four mice per group were tested 
on day 21. P<  0.05 for group A vs. C and D on day 7 and groups A and B 
vs. C on day 21. 
~: 24-h net percent increase ~  24-h percent swelling response of immunized 
group that received TNP-coupled cells, minus 24-h percent swelling response 
of nonimmunized mice that were challenged simultaneously with 1% PCL. 
§ Not done. 
TASTE  II 
Dominance of CS Induced by Hapten-coupled Splenic DC 
Over a Tolerogenic Dose of TNBS* 
Type of TNP- 
coupled spleen 
Group  cells (3 ×  10  r)  Tolerogen 
injected intra- 
venously 
24-h net percent increase 
in ear swelling +  SD:]: 
Day 7  Day 21 
A  DC  --  19+3  19+  1 
B  DC  TNBS  24 ::l: 5  23:1:3 
C  M#  --  21 +6  0+4 
D  M~  TNBS  0 +  2  4 ::t: 4 
* Table II shows the results of a single experiment in which each experimental 
group consisted of four mice. These animals were challenged at day 7 and 
then rechallenged at day 21. P <  0.05 for groups A, B, and C  vs. D on day 
7 and groups A and B vs. C and D on day 21. 
:~ 24-h net percent  increase =  24-h percent swelling response of immunized 
group that received TNP-coupled cells, minus 24-h percent swelling response 
of nonimmunized mice that were challenged simultaneously with 1% PCL. 
was  detectable  at  7  and  21  d  after  immunization.  In  contrast  (in  these  two  experi- 
ments),  similar numbers  of TNP-conjugated  Mth failed  to  induce  immunity  to  PCL 
at  day  7 or at day  21.  Thus,  splenic DC,  like epidermal  Langerhans  cells  (1), have a 
special capacity to present antigen after intravenous injection, such that persistent CS 
ensues.  Splenic Mth, like PEC  induced  by injection of oil or thioglycollate  (1), are less 
well-equipped  to induce this type of persistent response. 
Immunity Induced by TNP-DC: Effect of Coimmunization  with a  Tolerogenic Dose of TNBS 
(Table II).  Although  TNP-coupled  splenic Mqb failed to induce CS after intravenous 
injection  in  the  experiments  presented  in  Table  I,  this  was  not  always  the  case. 
Occasionally,  these  cells  induce  CS.  Because  previous  work  suggested  that  all  Ia  ÷ 
glass-adherent  cells could  present  antigen  effectively  if suppressor  mechanisms  were 
bypassed  (1),  we  considered  the  possibility  that  when  TNP-coupled  glass-adherent 1348  SPECIALIZED ANTIGEN-PRESENTING CELLS 
TABLE III 
Induction of CS to PCL by TNP-coupled PEC Induced by Various Activators* 
Group  PEC stimulator 
24-h net percent increase 
in ear swelling  + SD:I: 
Day 7  Day 14 
A  None§  -  1 +-- 2  ND 
B  IFA  5 ±  2  2 ±  5 
C  B. pertussis vaccine  2 ±  1  ND]] 
D  Thioglycollate  medium  I ± 5  0 ± 6 
E  CFA  15 ± 3  i3 ± 2 
* Mice were injected intravenously  with 5 × 106 TNP-PEC and 7 or 14 d later 
their ears were challenged with 1% PCL. The data were compiled from four 
independent experiments in which each experimental group consisted  of four 
to five animals. Each regimen was tested at least twice. P < 0.05 for groups 
A, BT"U, and D vs. E on day 7 and groups B and D vs. E on day 14. 
:~ 24-h net percent increase ffi 24-h percent swelling response of immunized 
group that received  TNP-coupled cells, minus 24-h percent swelling  response 
of nonimmunized mice that were challenged simultaneously  with 1% PCL. 
§ Unstimulated peritoneal cells. 
[I Not done. 
spleen  cells  induce  immunity after  intravenous injection, they  do  so  by  avoiding 
suppression.  To  test  this  notion,  we  performed  several  experiments  in  which  we 
immunized mice intravenously with  TNP-labeled cells and at  the  same  time gave 
them a tolerogenic dose of TNBS. The results in Table II show that on those occasions 
when CS is induced by TNP-coupled splenic Mq~, the response is different from that 
induced by TNP-DC in two ways:  (a)  it is completely suppressed by concommitant 
injection of TNBS  and  (b)  it  vanishes by day  21,  even when  no other  tolerogenic 
stimulus  is  presented.  Most  likely,  the  waning of  the  response  is  because  of  its 
sensitivity to  regulatory  suppressive  mechanisms.  Thus,  our  results  show  in  two 
different ways that  the  immune response induced by TNP-DC is more resistant to 
suppression than  is  the  response induced by TNP-Mq~.  Futhermore, the  failure of 
TNBS injection to diminish the response in mice immunized with TNP-DC indicates 
that these cells induce a  truly suppressor-resistant response, not that they simply fail 
to activate suppression. 
Studies  of  CS  Induced  by  TNP-coupled  PEC  Induced  by  Mycobacteria  (Table  IH). 
Intravenous injection of TNP bound to resident peritoneal cells or PEC stimulated by 
IFA, B. pertussis  vaccine, or thioglycollate medium failed to induce detectable CS to 
PCL  at  day  7  or  day  14  after  immunization. In addition, subsequent attempts  to 
sensitize these nonresponding mice by skin painting with PCL ~24 h  after primary 
challenge also  failed  to  induce CS  (data  not  shown).  Thus, TNP-conjugated PEC 
that were elicited by these means failed to induce immunity and appeared to induce 
unresponsiveness when injected intravenously. In contrast, TNP conjugation of PEC 
stimulated by CFA  (containing heat-killed H37Ra mycobacteria) induced CS  that 
was elicited at  day  7 and still elicitable at  day  14  after intravenous immunization. 
Thus, TNP-conjugated PEC stimulated by mycobacteria (TNP-CFA-PEC) not only 
failed to  induce unresponsiveness to  PCL but had  acquired the capacity to  induce 
immunity to PCL when administered by the intravenous route. Furthermore, like CS 
induced by skin-painting with PCL, or intravenous immunization with TNP-conju- BRITZ,  ASKENASE, PTAK, STEINMAN, AND GERSHON  1349 
gated epidermal Langerhans cells (1) or splenic DC (Tables I and II), CS induced by 
TNP-CFA-PEC was relatively long-lived. 
Effect  of Varying Cell Numbers on the Induction of CS with  TNP-conjugated  Cells  (Table 
IV).  Intravenous injection of 5  ×  107 haptenated spleen cells is a standard protocol 
for the induction of unresponsiveness to CS (3), whereas only 5 ×  106 TNP-CFA-PEC 
given intravenously was needed to immunize mice for CS. To determine whether this 
qualitative difference was a  function of cell number and/or dose of antigen, varying 
numbers of TNP-conjugated PEC  or  spleen cells were  injected intravenously into 
mice that were challenged at day 14. TNP-CFA-PEC were capable of inducing CS at 
doses of 5 ×  107 or 5 ×  106 cells but not at a dose of 5 ×  105 cells. Hapten-conjugated 
IFA-PEC or spleen cells, however, failed to induce CS at all doses tested. Thus, the 
immunizing potential of TNP-CFA-PEC remained intact at higher numbers of cells 
and disappeared when too few cells were injected. Neither increasing nor decreasing 
the  dose of hapten-conjugated IFA-PEC or spleen cells gave  them  the capacity to 
induce immunity by intravenous injection. These results strongly suggest that quali- 
tative and not simple quantitative differences account for the difference in immunizing 
capacity of the two cell types. 
Estimation  of Relative  TNP Content of Hapten-conjugated Cells (Table  V).  The data in 
Table IV are consistent with the idea that  induction of CS with TNP-CFA-PEC is 
not a result of a cellular dose effect. The total amount of TNP injected, however, may 
be a  crucial determinant of immunogenicity. Thus, it was  important to  quantitate 
the number of haptenic determinants that were injected into the mice. To address 
this question, equal numbers of haptenated or nonhaptenated cells were incubated 
with  an excess of 125I-MOPC-315, a  TNP-binding myeloma protein, for 30  min at 
4°C. After extensive washing, cells were transferred to new tubes for counting. The 
results (Table V) allow comparison of the average number of counts bound by spleen 
TABLE  IV 
Induction of CS to PCL by TNP-coupled Cells: Dose Response* 
Group  Cells injected intravenously 
24-h net percent 
increase in ear 
swelling ± SD on 
day 14~ 
A  5 ×  107 TNP-CFA-PEC  21 ± 5 
B  5 ×  106 TNP-CFA-PEC  20 ± 3 
C  5 ×  105 TNP-CFA-PEC  6 ± 3 
D  5 ×  107 TNP-IFA-PEC  0 ± 0 
E  5 ×  106 TNP-IFA-PEC  3 ± 4 
F  5 X 105 TNP-IFA-PEC  4 ± 4 
G  5 ×  10  7  TNP-spleen cells  0 +__ 4 
H  5 X 10  6 TNP-spleen cells  3 ± 2 
I  5 ×  10  5 TNP-spleen cells  4 ± 3 
* Table IV shows the results of a single  experiment in which each experimental 
group consisted of four animals. P < 0.05 for groups A and B vs. C, D, E, F, 
G, H, and I. 
:~ 24-h net percent increase =  24-h percent swelling response of immunized 
group that received  TNP-coupled cells, minus 24-h percent swelling  response 
of nonimmunized mice that were challenged simultaneously with 1% PCL. 1350  SPECIALIZED  ANTIGEN-PRESENTING  CELLS 
TABLE  V 
Binding of l2SI-MOPC 315 to Haptenated vs. Nonhaptenated Cells* 
Counts per 
Hapten  minute 
Group  Cell type  coating  bound 
A  CFA-PEC  TNP  2,780 
B  CFA-PEC  None  215 
C  IFA-PEC  TNP  2,686 
D  IFA-PEC  None  62 
E  Thioglycollate-PEC  TNP  12,515 
F  Thioglycollate-PEC  None  746 
G  Spleen cells  TNP  7,046 
H  Spleen cells  None  451 
I  None  None  514 
* 5 ×  10  e haptenated or nonhaptenated cells were incubated with an excess of 
a~SI-MOPC-315 (sp act ~  1.8 x  10  n Ci/mol) for 30 min on ice, Results are 
the average of triplicate tubes. 
TABLE  VI 
Failure of Nonhaptenated CFA-PEC to Provide an Adjuvant Effect 
for TNP Presented on IFA-PEC* 
Group  Cells injected intravenously 
24-h net per- 
cent increase in 
ear swelling + 
SD at day 21~: 
A  5 ×  10  e TNP-CFA-PEC  15 :i: 4 
B  5 x  10  6 TNP-IFA-PEC  2 _+ 3 
C  5 ×  10  e TNP-IFA-PEC  +  5 ×  10  6  3 +- 3 
CFA-PEC 
* Ceils were mixed and injected in a vol of 0.4 ml HBSS via the tail vein. Each 
experimental group consisted of four mice. P <  0.05 for group A vs. B and 
C. 
~: 24-h net percent increase =  24 h  percent swelling response of immunized 
group that received TNP-coupled cells, minus 24-h percent swelling response 
of nonimmunized mice that were challenged simultaneously with i% PCL. 
cells  or  PEC  stimulated  by  CFA,  IFA,  or  thioglycollate  medium.  Although  spleen 
cells  and  thioglycollate-stimulated  PEC  bound  2-5  times  more  counts  than  PEC 
stimulated  by CFA  or IFA,  it was clear that  binding  of MOPC-315  to CFA  or IFA- 
PEC  was  equivalent.  Since  CFA  and  IFA-PEC  were  roughly  similar  in  size,  as 
determined  by  microscopic  inspections,  the  differences  in  immunizing  potential 
between  these cells cannot  be accounted  for simply on  the basis of antigen  (hapten) 
dose. 
Requirement for  Haptenation  of the  CFA-stimulated  PEC for  Antzgen  Presentation  (Table 
I11).  To  determine  whether  the differences  in  immunity  induced  by hapten-conju- 
gated CFA  and  IFA-PEC  were actually related to antigen presentation  by these cells 
or result  from  an  ill-defined  adjuvant  effect  of the  mycobacteria  on  bystander  cells, 
we tested whether  hapten  conjugation  to the CFA-stimulated  PEC  was obligatory for BRITZ,  ASKENASE,  PTAK,  STEINMAN,  AND  GERSHON 
TABLE  VII 
Dominance of CS Induced by TNP-CFA-PEC: 
Effect of Coimmunization with TNBS 
1351 
24-h net per- 
Group  cent increase 
(4 mice/  Immunogen*  Tolerogen~:  in ear swelling 
group)  ±  SD at 
day 7§ 
A  TNP-CFA-PEC  --  15 ±  6 
B  TNP-CFA-PEC  TNBS  21  ±  4 
C  TNP-IFA-PEC  --  7 ±  l 
D  TNP-IFA-PEC  TNBS  2 ±  1 
E  5% PCL topically  --  27 ±  3 
F  5% PCL topically  TNBS[]  4 ±  4 
* 5 ×  106 TNP-coupled cells were injected intravenously via the tail vein. 
1: Several  minutes after injection  of cells,  4  mg TNBS was injected  into the 
retroorhital venous plexus. 
§ Each experimental group consisted of four to five mice. P <  0.05  for groups 
A, B, and C vs. D. 24-h net percent increase -- 24-h percent swelling response 
of immunized  group  that  received  TNP-coupled  cells  or  PCL  topically, 
minus  24-h  percent  swelling  response of nonimmunized  mice  that  were 
challenged simultaneously with 1% PCL. 
]] 4 mg TNBS was injected intravenously 7 d before topical application of 5% 
PCL. 
TABLE  VIII 
Adoptive Transfer of CS to PCL Induced by TNP-CFA-PEC 
or TNP-IFA-PEC* 
Group  Immunization 
24-h net percent increase 
in ear swelling ±  SD at 
day 7~ 
Donor  Recipient 
A  5% PCL  30 ±  6  15 ±  5 
B  TNP-CFA-PEC (5 x  10s)§  16 ±  3  7 ±  2 
C  TNP-IFA-PEC (5 ×  106)  10 ±  1  0 ±  3 
CS at day  14 
Donor  Recipient 
D  5% PCL  3I ±  5  ll  :t: 5 
E  TNP-CFA-PEC (5 ×  106)  23 ±  1  13 +  6 
F  TNP-IFA-PEC (5 ×  106)  0 ±  5  0 +  3 
* Table  VlIl  shows data  combined from three  independent  experiments in 
which donor experimental groups consisted of four animals, and  recipient 
experimental groups consisted of six animals. P<  0.05 for groups A, B, C, D, 
and E  vs. F  (donors) and P <  0.05  for groups A and B vs. C  and groups D 
and E  vs.  F  (recipients). 
~: 24-h  net  percent  increase ~  24-h  percent swelling response of immunized 
groups that were actively sensitized or received  immune cells,  minus 24-h 
percent  swelling  response  of  nonimmunized  mice  that  were  challenged 
simultaneously with 1% PCL. 
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antigen  presentation.  The  results  in  Table  VI  show  that  the  inability  to  induce 
persistent immunity with TNP-IFA-PEC cannot be overcome by coadministration of 
nonhaptenated CFA-stimulated PEC. 
Effect  of  Coimrnunization  with  TNP-PEC  and  a  Tolerogenic Dose  of  TNBS  (Table 
VII).  Although  TNP-IFA-PEC  failed  to induce  CS  after intravenous  injection  in 
the experiments presented  in  Tables III, IV, and  VI, on some occasions these cells 
(like splenic M~ [Table II]) can induce CS. Thus we performed a series of experiments 
in which we coadministered a tolerogenic dose of TNBS to test whether CS induced 
by TNP-IFA-PEC was more sensitive to suppression than that induced by TNP-CFA- 
PEC. Intravenous injection of 4 mg TNBS 7 d before a sensitizing skin-painting with 
PCL blocked the induction of CS to PCL (groups E and F). Nonetheless, when TNP- 
CFA-PEC were injected into mice simultaneously with this dose of TNBS, CS at day 
7  was  undiminished  when  compared  with  mice  immunized  with  TNP-CFA-PEC 
alone  (groups A  and B).  In this experiment, hapten-conjugated  IFA-PEC were very 
weakly immunogenic, in contrast to earlier experiments in which they failed to induce 
CS  by  the  intravenous  route.  However,  coadministration  of TNBS  prevented  the 
development of this CS. Thus, although both IFA- and CFA-stimulated PEC provided 
effective antigen presentation, CS induced  by TNP-CFA-PEC was not only quanti- 
tatively greater, but was also insensitive to suppression by coadministration of TNBS. 
The Ability  to  Adoptively  Transfer  CS Induced by  Hapten-conjugated  CFA  vs.  IFA-PEC 
(Table VIII).  Since the initial demonstrations by Dresser (10) and Celada (11) it has 
been shown repeatedly that some immune responses are hard to adoptively transfer 
without inactivating the recipient's suppressor T  cells (12).  Thus, we reasoned that if 
the effector cells of CS that arise after immunization with TNP-CFA-PEC are truly 
suppressor resistant, then they should be better able to transfer CS than effector cells 
that  are raised  by immunization  with  TNP-IFA-PEC.  The results  shown  in  Table 
VIII demonstrate that the CS elicited at both day 7 and 14 in mice topically sensitized 
with PCL could be adoptively transferred into normal recipients. The magnitude of 
the ear swelling response induced by TNP-CFA-PEC was less than that obtained by 
skin  painting,  but  the efficiency of transfer was at least as good.  In contrast,  TNP- 
IFA-PEC induced  a  moderate level of CS at day 7 that was no longer detectable by 
day  14.  Furthermore,  day-7  CS  that  was  induced  by  TNP-IFA-PEC  was  more 
sensitive to suppressor mechanisms that prevent cell transfer of CS than were T  cells 
induced by TNP-CFA-PEC. 
Discussion 
The  results  we  have  presented  in  this  manuscript  taken  together  with  previous 
results (1) suggest that the type of cell that presents antigen to the immune system is 
of great importance in determining both the qualitative and quantitative aspects of 
the immune response that  an antigen will stimulate.  We have identified  two major 
classes  of APC  that  can  be  distinguished  from  one  another  by  the  sensitivity  to 
suppression of the immune response they induce. 
Previous studies have shown that TNP-labeled Ia  + PEC can induce evanescent CS 
if injected subcutaneously. However, induction of CS by administration of these cells 
by the  intravenous route requires  pretreatment  of the host  with  cyclophosphamide 
(1).  On the other hand, TNP-labeled epidermal Langerhans cells injected by either 
route are immunogenic  (1).  Thus, the proficiency of Langerhans cells in presenting BRITZ,  ASKENASE, PTAK,  STEINMAN,  AND  GERSHON  1353 
antigen intravenously did not depend upon avoidance of suppressor cell induction in 
the spleen (accomplished by subcutaneous injection) or elimination of suppressor cells 
by cyclophosphamide (13), but was a result of their induction of suppressor-resistant 
effector cells (1). 
We have now shown that another naturally occurring APC type, i.e., splenic DC, 
can act like Langerhans cells and that this specialized capacity to present antigen can 
also be induced in peritoneal exudates by mycobacteria. We have further emphasized 
the T  suppressor resistance of the CS response induced by DC- or CFA-induced PEC 
by showing that  the  immune  response that  occurs after they present  TNP  to  the 
system is: (a) long lived, (b) not affected by coadministration intravenously of a highly 
tolerogenic dose of TNBS, and (c) can be adoptively transferred to antigenically naive 
recipients. This last point is particularly helpful in  determining the mechanism by 
which these specialized APC work because of the recent findings of Iverson et al.  2, 
who showed that adoptive transfer of CS  to normal  recipients required a  cell that 
could  protect T  effector cells  from  the  action  of host  suppressor T  cells  that  are 
activated by the adoptively transferred cells. These protector cells can be distinguished 
from other T  cells by their expression of a  unique cell surface antigen coded for by 
genes in  the I-J subregion of the major histocompatibility complex and  have been 
referred to as contrasuppressor cells  (14).  Adoptive immunity does not  require the 
presence of these contrasuppressor cells when  the recipient's suppressor system has 
been diminished by treatment with low doses of cyclophosphamide. 
All three of the distinctive features of the CS response induced by the specialized 
APC we have tested can be explained by the induction of a response that is relatively 
resistant  to  normal  suppressor  mechanisms.  The  results  of the  adoptive  transfer 
experiments indicate that the resistance to suppression is mediated, at least in part, 
by contrasuppressor cells.  Taken together then, our results suggest  that  specialized 
APC not only activate helper and/or effector T  cells, but that they also activate the 
cells that comprise the contrasuppressor circuit (14,  15).  2 
The question of how these specialized APC induce suppressor-resistant effector cells 
and/or activate contrasuppressor cells remains to be determined. The amount of Ia 
antigen that APC express on their surface or the rate at which they shed these antigens 
into the local environment may influence the type of T  cell subset with which they 
interact. Thus, some T  cell subsets may have to recognize more self-major histocom- 
patibility complex-encoded antigen on the APC  to be activated. Alternatively--or 
additionally--specialized APC may present, in addition to antigen, other signals that 
activate special T  cell gene programs, including the one that makes T  cells resistant 
to suppression. This could be accomplished by modulating the numbers of receptors 
that  T  cells  express  for suppressor  factors.  Mechanisms  involving Ia  antigens  are 
particularly attractive because: (a) intensive immunization with mycobacterial adju- 
vants induces increased numbers of Ia  ÷ macrophages (5), (b) splenic DC express large 
amounts of Ia (4, 7), and (c) agents that inhibit turnover of Ia on cell surfaces diminish 
the ability of the treated cells to stimulate immune responses.  ~ However, Ia positivity 
per se cannot explain our results. Ia  + thioglycollate-induced TNP-PEC are needed to 
2 Iverson, G. M., W. Ptak, D. R. Green, and R. K. Gershon. The role of contrasuppression in the adoptive 
transfer of immunity. Manuscript submitted for publication. 
n Emerson, S. G. J. Pretell, W. Stock, G. M. Iverson, D. Murphy, and R. K. Gershon. Treatments which 
influence the expression  and  shedding of [a  antigens  inhibit  the ability of cells  to  stimulate  mixed 
lymphocyte reactions.  Manuscript submitted for publication. 1354  SPECIALIZED  ANTIGEN-PRESENTING  CELLS 
induce even the short-lived form of CS, and treatment with anti-Ia and complement 
eliminates  this.  Furthermore,  when  these same Ia  + cells are injected  intravenously, 
they induce tolerance (1).  Finally, the day-4 IFA- and CFA-PEC that induce the two 
types of CS do not grossly differ in numbers of Ia  + cells (-5%), as judged by indirect 
immunofluorescence in two separate experiments (our unpublished observations). 
Another possibility that must be considered stems from the finding that splenic DC 
express  high  levels of H-2D  as well  as  I-A  (4).  Because  cells  in  suppressor  circuit 
appear to be preferentially activated by allogeneic H-2D (16), it would not be at all 
surprising if contrasuppressor cells also had a predilection for reacting with antigen in 
association with H-2D. Thus, the reason that DC are such exceptionally good APC 
may be a  result of their high levels of Ia, which help them activate helper cells, and 
also of their high levels of H-2D, which help them present signals to the contrasup- 
pressor system. 
In the search for variables that might be important in explaining the differential 
ability of hapten-labeled CFA vs. IFA-activated PEC to induce persistent  CS reac- 
tions,  the numbers of APC  inoculated  and quantitation  of the number of haptenic 
groups per APC were examined. These factors, however, were not able to account for 
the observed differences. CFA may cause an influx of DC into the peritoneal cavity, 
which  has  been  identified  in  bacillus  Calmette-Gufirin-elicited  exudates  (17),  and 
some of the adjuvant properties of CFA may be attributed to the inducibility of this 
APC population. However, we should also emphasize that although TNP-labeled DC 
and TNP-CFA-PEC both have similar effects on the immune system, the mechanism 
by which they work need not be precisely the same. 
In sum, the results we have presented indicate that one of the important variables 
in determining the type of an immune response that an antigen will induce depends 
on the type of cell that  presents the antigen  to the regulatory T  cell system. When 
some specialized APC present the antigen, then the immune response will be, if not 
quantitatively stronger, certainly longer-lasting and harder to suppress. These attri- 
butes could be responsible for important  qualitative changes that  occur during  the 
course of an immune response such as the production of high affinity antibodies that 
take a long time to be generated and that, being highly sensitive to T  cell-suppressor 
mechanisms (18,  19), must be protected during the maturation and/or differentiation 
of precursor cells. 
Summary 
We have tested the ability of several types of trinitrophenyl (TNP)-labeled Ia  + cells 
to induce contact hypersensitivity (CS) after intravenous injection.  Most labeled cell 
types (spleen cells, splenic macrophages, various types of peritoneal°exudate cells) not 
only fail to induce CS after this type of inoculation but, rather, activate T  suppressor 
cells leading to specific immunological tolerance. Occasionally, some of these immu- 
nizing cells managed to bypass the T  suppressor system and  induced  CS.  In those 
cases the response was short-lived and could be blocked by concomitant injection of 
trinitrobenzelsulphonic acid (TNBS), a potent inducer of T  suppressor cells. 
In sharp contrast  to these results,  TNP-labeled  splenic dendritic  cells and  TNP- 
labeled  peritoneal-exudate  cells  induced  by  complete  Freund's  adjuvant  had  the 
following distinctive  features:  (a)  They were always able to sensitize when  injected 
intravenously, and the degree of sensitization they produced was roughly equivalent BRITZ, ASKENASE,  PTAK, STEINMAN,  AND GERSHON  1355 
to that achieved by cutaneous application of picryl chloride, the chemically reactive 
form of TNP.  (b)  The response they elicited was  long lived  (i.e., lasted for >3  wk). 
(c)  Their sensitizing capacity could not  be blocked by the concomitant  injection of 
TNBS.  (d) They elicited a response that could be adoptively transferred to untreated, 
normal recipients. 
These results indicate that the type of cell that first presents antigen to the immune 
system  plays  an  important,  even  essential,  role  in  determining  the  strength  and 
duration of the subsequent  immune  response.  In particular, the results suggest  that 
some special antigen-presenting cells can induce a  response that is relatively resistant 
to  host  suppressor mechanisms.  Evidence  that  they do so by activating contrasup- 
pressor cells is discussed. 
Received  for publication 23 September 1981 and in revised  form 2 February 1982. 
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